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داللة مستويات اجللوكوز يف الدم وتغرياته كعوامل تنبؤ بنتائج املرضى املصابني 
بتسمم فوسفيد األلومنيوم
اأرفند �شارما، برا�شانث بال�شربامينني، كريان جل، اأ�شي�ص بّله
abstract: Objectives: This study aimed to assess the prognostic significance of blood glucose levels and blood glucose 
alterations (i.e. hyper- or hypoglycaemia) among patients with aluminium phosphide (AlP) poisoning. Methods: This 
prospective observational study was conducted at the Postgraduate Institute of Medical Education & Research, Chandigarh, 
India, between January 2010 and June 2011. All patients presenting to the emergency department with a definitive history of 
AlP ingestion or symptoms compatible with AlP poisoning were included in the study. Blood glucose levels were recorded 
at presentation and every six hours thereafter. Alterations in blood glucose levels and other clinical and laboratory variables 
were subsequently compared between survivors and non-survivors. Results: A total of 116 patients with AlP poisoning 
were identified. Of these, 57 patients (49%) survived and 59 patients (51%) died. At presentation, the mean blood glucose levels 
of survivors and non-survivors were 119.9 ± 35.7 mg/dL and 159.7 ± 92.5 mg/dL, respectively (P <0.001). In comparison to 
the survivors, non-survivors had significantly higher heart rates, total leukocyte counts, blood glucose level alterations  and 
serum creatinine levels (P <0.050). In addition, systolic blood pressure, Glasgow coma scale scores, arterial blood gas pH and 
bicarbonate values and duration of hospital stay was significantly lower compared to survivors (P <0.001). However, neither 
blood glucose levels at admission nor blood glucose alterations correlated independently with mortality in a multivariate 
analysis. Conclusion: The role of blood glucose level alterations in predicting patient outcomes in AlP poisoning cases 
remains inconclusive. Further studies with larger sample sizes are required.
Keywords: Aluminum Phosphide; Poisoning; Blood Glucose; Hyperglycemia; Hypoglycemia; Mortality; Prognostic Factors; 
India.
امللخ�ص: الهدف: هدفت هذه الدرا�شة اإىل تقييم دللة م�شتويات اجللوكوز يف الدم وتغرياته )زياده اأو نق�شان( كعوامل تنبوؤ بنتائج املر�شى 
امل�شابني بت�شمم فو�شفيد الألومنيوم. الطريقة: اأجريت هذه الدرا�شة الر�شدية يف معهد الدرا�شات العليا للتعليم الطبي والبحوث يف �شانديغار، 
الهند، يف الوقت بني يناير 2010 و يونيو 2011 على جميع املر�شى القادمني اإىل ق�شم الطوارئ بعد التاأكد من ابتالع فو�شفيد الألومنيوم اأو 
لديهم اأعرا�ص متوافقة مع هذا الت�شمم. مت ت�شجيل م�شتويات اجللوكوز يف الدم عند قدومهم وكل �شت �شاعات بعد ذلك. متت بعد ذلك مقارنة 
التغيريات يف م�شتويات اجللوكوز يف الدم وغريها من املتغريات ال�رسيرية واملخربية بني الناجني وغري الناجني من الت�شمم. النتائج: مت 
حتديد جمموعه 116 مري�شا اأ�شيبو بت�شمم فو�شفيد الألومنيوم. من هوؤلء، جنا 57 مري�شا )%49( وتويف 59 مري�شا )%51(. عند القدوم اإىل 
ق�شم الطواريء، كان متو�شط م�شتويات ال�شكر يف الدم للناجني وغري الناجني 35.7 ± 119.9 ملغ/دي�شيلرت و 92.5 ± 159.7 ملغم/دي�شيلرت ، على 
التوايل )P >0.001(. كان لدى غري الناجني باملقارنة مع الناجني قيم اأعلى ب�شكل ملحوظ ملعدل �رسبات قلب، اأعداد كريات الدم البي�ص، 
تغريات م�شتوى اجللوكوز وم�شتويات الكرياتينني يف الدم )P >0.050(. بالإ�شافة اإىل ذلك، كان �شغط الدم النقبا�شي ومقيا�ص غيبوبة 
.)P >0.001( غال�شكو ودرجة احلمو�شة وم�شتوى البيكربونات يف الدم ال�رسياين ومدة الإقامة يف امل�شت�شفى اأقل بكثري مقارنة بالناجني
ومع ذلك، ل ترتبط م�شتويات اجللوكوز يف الدم عند القدوم ول تغريات اجللوكوز يف الدم ب�شكل م�شتقل مع معدل الوفيات يف التحليل متعدد 
املتغريات. اخلال�صة: ل يزال دور تغريات م�شتوى اجللوكوز يف الدم يف التنبوؤ بنتائج املر�شى يف حالت ت�شمم فو�شفيد الألومنيوم غري 
حا�شم. مطلوب مزيد من الدرا�شات مع اأحجام عينة اأكرب.
الكلمات املفتاحية: ت�شمم فو�شفيد الألومنيوم؛ جلوكوز الدم؛ ارتفاع ال�شكر يف الدم؛ نق�ص ال�شكر يف الدم؛ معدل الوفيات؛ عوامل التنبوؤ؛ الهند.
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Advances in Knowledge
- Elevated blood glucose levels have been previously identified as an indicator of poor prognosis in cases of aluminium phosphide (AlP) 
poisoning. However, the current study found that blood glucose level alterations—namely, hyper- or hypoglycaemia—were not associated 
with mortality in AlP cases.
Application to Patient Care
- Based on the findings of the current study, blood glucose level alterations should not be considered predictors of poor patient prognosis 
in AlP poisoning cases. Patients should therefore be assessed based on a range of clinical and laboratory parameters.
doi: 10.18295/squmj.2018.18.03.006
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In India, aluminium phosphide (alp) is the most commonly encountered poison after anti-cholinesterase.1 As a pesticide, AlP is used exten-
sively to protect stored products and crops and is 
available in the form of pellets, tablets or compressed 
discs. In northern India, an epidemic of AlP poisoning 
was reported in 1988 in which 285 cases of AlP ingestion 
were documented, most of which were intentional/
suicidal.2 Although the toxicokinetic properties of AlP 
are poorly understood, its toxicodynamic properties 
are exerted by phosphine (PH3), which is released in 
the stomach when it comes into contact with moisture 
or hydrochloric acid and results in the inhibition of 
cytochrome C oxidase and a release of free oxygen 
radicals, causing oxidative stress.3,4 After oral ingestion, 
PH3 is quickly absorbed into the body, resulting in 
systemic toxicity, with death usually resulting from 
cardiovascular dysfunction.5 Phosphides may also be 
absorbed in their unhydrolysed salt form.6 
Apart from a definitive history of ingestion, a diag- 
nosis of AlP poisoning can be established by the odour 
of the patient’s breath, which often smells of garlic or 
decaying fish, although the former symptom is also 
seen in calcium carbide poisoning cases.7–9 Other early 
symptoms include nausea, vomiting, epigastric and retro- 
sternal pain, anxiety, agitation and dyspnoea.7 In addition, 
the diagnosis can also be made by silver nitrate testing 
of the gastric fluid or breath.9 Peripheral circulatory 
failure and shock are early signs indicating fatal tox-
icity.7 The mortality rate in AlP poisoning cases varies 
from 30–100% and depends upon the dose and freshness 
of the poison, the onset of clinical manifestations, time 
until presentation, duration and severity of shock, time 
until vomiting and treatment modality. The main compl- 
ications observed in fatal AlP poisoning cases are 
cardiac dysrhythmias, severe metabolic acidosis, shock, 
respiratory distress syndrome and hypomagnesaemia.7
Prognostic factors that may predict poor outcomes 
in AlP poisoning cases include hyperglycaemia, hypo- 
tension, acidosis, leukocytosis, hyperuricaemia, electro- 
cardiography abnormalities, high Acute Physiology and 
Chronic Health Evaluation scores, high Simplified Acute 
Physiology Scores, low Glasgow coma scale scores, acute 
renal failure, low prothrombin rates, methaemoglobin-
aemia and the use of inotropes and mechanical vent- 
ilation.10–14 Serial blood glucose monitoring is a conv- 
enient and easy method of assessing hypo- or hyper-
glycaemia, particularly in primary healthcare settings 
with limited resources. The current study aimed to 
determine the incidence of blood glucose level alter- 
ations in patients with AlP poisoning and the correl-
ations between blood glucose levels and alterations 
and mortality.
Methods
This prospective observational study was conducted at the 
Postgraduate Institute of Medical Education & Research, 
a tertiary referral centre in Chandigarh, northeast India, 
from January 2010 to June 2011. All patients presenting 
to the emergency department during this period with a 
definitive history of AlP ingestion or symptoms comp-
atible with AlP poisoning—including vomitus smelling 
of decaying fish or garlic, severe hypotension or shock, 
metabolic acidosis and abnormalities in cardiac rate or 
rhythm—were included in the study. Cases in which 
the ingestion of AlP was doubtful or with concom- 
itant ingestion of other drugs or alcohol were excluded, 
as were patients with a history of dextrose administration 
prior to presentation or those with diabetes mellitus. 
The vital signs of the patients were assessed, including 
their blood pressure (BP), heart rate and respiratory 
rate. Temperature and oxygen saturation were recorded 
using a pulse oximeter. Blood glucose levels were recorded 
using the Hitachi Modular Analytics System P800 chem- 
istry analyser (Roche Diagnostics K.K., Tokyo, Japan), 
after appropriate calibration and quality control measures. 
Alterations in blood glucose levels were defined as the 
occurrence of either hyperglycaemia (random blood gluc- 
ose levels of >200 mg/dL) or hypoglycaemia (random 
blood glucose levels of <55 mg/dL) at admission or any 
point during hospital stay.15,16 A complete blood count 
was performed along with biochemical tests to determine 
serum sodium, potassium, urea, creatinine and bilirubin 
levels. Arterial blood gas (ABG) analyses were performed 
to determine pH, partial pressure of oxygen, bicarbonate 
value, partial pressure of carbon dioxide and base excess 
for the given fraction of inspired oxygen. All clinical and 
laboratory measurements were recorded at admission, 
every six hours thereafter for the first 72 hours and then 
every 24 hours until discharge. If necessary, certain 
variables were assessed more frequently, depending 
on the clinical condition of the patient. 
All patients received standard supportive treatment, 
including basic emergency medical care and gastro-
intestinal decontamination (i.e. gastric lavage). Hypo-
glycaemic patients were treated with rapid intravenous 
infusions of two units of 100 mL of 25% dextrose 
solution and then maintained with 5% dextrose or 
5% dextrose and normal saline solution, titrated 
according to electrolyte levels and glycaemic status.17,18 
A maximum of two units of 5% dextrose and normal 
saline solution up to a total of 500 mL daily were admin-
istered as a maintenance regimen for euglycaemic patients, 
titratred according to the patient’s input-output status. 
Hyperglycaemic patients were treated initially according 
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to a continuous insulin infusion protocol and, subseq-
uently, via a subcutaneous insulin regimen.19
The statistical analysis was performed using the 
Statistical Package for the Social Sciences (SPSS), Version 
22.0 (IBM Corp., Armonk, New York, USA). Various 
clinical and laboratory parameters were compared bet- 
ween survivors and non-survivors, with the primary vari- 
ables of interest being blood glucose level at presentation 
and the frequency of blood glucose alterations at adm- 
ission or during hospital stay. The normality of quant- 
itative variables was determined using the Kolmogorov-
Smirnov test. For normally distributed data, means 
and standard deviations were calculated for continuous 
variables while frequencies, percentages and proportions 
were calculated for qualitative variables. A t-test was 
used to compare the mean differences between the study 
groups and a Chi-squared test was used to compare 
proportions. Univariate and multivariate logistic regression 
analyses were conducted with mortality as the dependent 
variable. Independent variables found to be significant 
on the univariate analysis were included in the logistic 
regression model and analysed using the Enter method. 
Random blood glucose levels were considered to be a 
continuous variable in the univariate and multivariate 
regression analyses, whereas alterations in blood gluc-
ose levels were considered categorical (i.e. nominal) 
variables. A P value of <0.050 was considered statist-
ically significant. 
This study was conducted with prior approval from 
the institutional ethics committee. Written informed 
consent was obtained from all patients or their relatives 
prior to participation in the study.
Results
A total of 116 cases of AlP poisoning were identified. Of 
these, 59 patients (51%) were 15–25 years old, 32 (28%) 
were 26–35 years old, 14 (12%) were 36–45 years old, 
nine (8%) were 46–55 years old and two (2%) were 
over 55 years old. The most frequent symptoms were 
vomiting (99%) and epigastric pain (61%), followed by 
dyspnoea (41%) and altered sensorium (28%). The median 
length of hospital stay was 18 hours (range: 5–42 hours). 
At presentation, 12 (10%) patients had hypoglycaemia, 
16 (14%) had hyperglycaemia and 88 (76%) had normal 
blood glucose levels. 
In total, 57 patients (49%) survived and 59 patients 
(51%) died. The cause of death was refractory cardiogenic 
shock in 20 patients (34%), multiorgan dysfunction syndr- 
ome in six patients (10%), cardiac arrhythmias in five 
patients (8%) and respiratory failure in four patients (7%). 
The cause of death in the remaining 24 cases (41%) could 
not be determined. In terms of blood glucose alterations, 
all of the patients with hyperglycaemia, nine patients (75%) 
Table 1: Characteristics of patients with aluminium 
phosphide poisoning (N = 116)







Age in years 28 ± 9 30 ± 11 0.399
Male gender, n (%) 38 (67) 33 (56) 0.235
Form of AlP ingested, n (%)
Powder 40 (70) 51 (86)
0.051Tablet 11 (19) 3 (5)
Unknown 6 (11) 5 (9)
Vital signs at admission
Heart rate in bpm 101 ± 14 109 ± 11 0.001
SBP in mmHg 106 ± 29 77 ± 20 <0.001
Glasgow coma score 12.9 ± 0.1 2.3 ± 0.8 <0.001
Blood glucose measurements
Blood glucose level* 
in mg/dL
119.9 ± 35.7 159.7 ± 92.5 <0.001
Frequency of blood 
glucose alterations,† 
n (%)
3 (5) 25 (42) <0.001‡
Biochemistry results
Serum sodium in 
mmol/L
142.5 ± 7.0 144.6 ± 7.4 0.058
Serum potassium in 
mmol/L
4.0 ± 0.7 4.1 ± 1.1 0.216
Serum creatinine in 
mg/dL
0.8 ± 1.0 1.4 ± 1.2 0.003
Serum bilirubin in 
mg/dL
0.9 ± 0.6 0.8 ± 0.5 0.116
TLC × 103 per mm3 8.6 ± 3.4 12.2 ± 5.1 0.005
ABG measurements
pH 7.3 ± 0.7 7.1 ± 1.3 <0.001




and presentation in 
hours (IQR)
4 (3–6) 4 (2–7) 0.816§
Median dextrose 
administered in g 
(IQR)
62 (25–125) 75 (43–106) 0.856§
Median LOS in 
hours (IQR)
36 (24–66) 5 (2–12) <0.001§
SD = standard deviation; AlP = aluminium phosphide; bpm = beats 
per minute; SBP = systolic blood pressure; TLC = total leukocyte count; 
ABG = arterial blood gas; HCO3 = bicarbonate; IQR = interquartile 
range; LOS = length of stay.
*Assessed via random blood glucose tests. †Defined as either hyper- 
glycaemia (random blood glucose levels of >200 mg/dL) or hypo-
glycaemia (random blood glucose levels of <55 mg/dL). ‡Using a 
Mann-Whitney U test. §Using a Chi-squared test.
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with hypoglycaemia and 34 patients (39%) with normal 
blood glucose levels died. 
Both mean blood glucose levels (159.7 ± 92.5 mg/dL 
versus 119.9 ± 35.7 mg/dL; P <0.001) and the frequency 
of blood glucose alterations (5% versus 42%; P <0.001) 
were significantly higher among non-survivors comp-
ared to survivors. This was also the case for heart rate 
(109 ± 11 beats per minute [bpm] versus 101 ± 14 bpm; 
P = 0.001), total leucocyte count (12.2 ± 5.1 × 103 per mm3 
versus 8.6 ± 3.4 × 103 per mm3; P = 0.005) and serum 
creatinine levels (1.4 ± 1.2 mg/dL versus 0.8 ± 1.0 mg/dL; 
P = 0.003). In addition, non-survivors had significantly 
lower systolic BP at admission (77 ± 20 mmHg versus 
106 ± 29 mmHg), Glasgow coma scale scores (2.3 ± 0.8 
versus 12.9 ± 0.1), arterial blood gas pH (7.1 ± 1.3 versus 
7.3 ± 0.7) and bicarbonate values (11.3 ± 5.6 versus 
16.3 ± 4.8) and median duration of hospital stay 
(5 versus 36 hours) compared to survivors (P <0.001 each) 
[Table 1]. 
Statistically significant variables from the univariate 
analysis were subsequently included in a logistic regr-
ession model to predict mortality at a 95% confidence 
interval. Although systolic BP at admission (P = 0.029) 
and duration of hospital stay (P = 0.008) remained 
significant, neither blood glucose levels nor blood glucose 
alterations were found to be independent predictors of 
mortality (P >0.050 each) [Table 2].
Discussion
According to international recommendations, blood 
glucose levels should be maintained at 140–180 mg/dL 
for normoglycaemic patients and 180–200 mg/dL 
for previously diabetic individuals.20 Both the hypo- 
and hyperglycaemic effects of AlP are attributable to 
the wide variety of changes in magnesium, calcium, 
phosphate, citrate and cortisol levels that result from 
AlP poisoning.11,21 These biochemical changes can act 
as either stimulatory or inhibitory modulators of the 
enzymes and hormones that catalyse and regulate the 
metabolism of glucose. Therefore, depending on the 
type of biochemical change, AlP poisoning can result 
in the elevation or decrease of blood glucose levels or 
neither.11,21
Nevertheless, the specific mechanism by which 
AlP poisoning causes hypoglycaemia is poorly under-
stood. Possible explanations include as a result of liver 
damage due to the release of PH3 gas and the toxic effects 
of PH3 on the adrenal cortex, leading to decreased cor- 
tisol levels.22 In addition, certain symptoms of AlP pois- 
oning such as recurrent vomiting and lack of appetite 
may also play a role in the development of hypogly-
caemia. In contrast, hyperglycaemia occurs due to either 
the stimulation of cortisol, glucagon and adrenaline secr- 
etion or the inhibition of insulin synthesis.11,21 A glucose- 
insulin-potassium infusion has been suggested as a pot- 
ential therapeutic modality in the treatment of hyper-
glycaemia in AlP poisoning.23
Among critically-ill patients, blood glucose alter-
ations have been associated with prolonged hospital stays 
as well as increased mortality.20,24 However, to the best 
of the authors’ knowledge, only one previous study has 
examined the relationship between hyperglycaemia and 
AlP poisoning outcomes. Mehrpour et al. published a 
prospective study of 45 patients with acute AlP pois- 
oning, of which 32 patients (71%) died.11 Non-survivors 
had significantly higher mean blood glucose levels than 
survivors (222.6 ± 20 mg/dL versus 143.4 ± 13.7 mg/dL; 
P = 0.021). Furthermore, blood glucose levels were an 
independent predictor of mortality in a multivariate 
analysis.11 This contradicts the findings of the current 
study in which alterations in blood glucose levels 
(i.e. either hyperglycaemia or hypoglycaemia) were 
not independent predictors of mortality. This may 
be because Mehrpour et al. utilised a different cut-
off value to indicate hyperglycaemia than that of the 
present study (>140 mg/dL versus >200 mg/dL).11
Table 2: Logistic regression model to predict mortality 








Heart rate −0.009 0.050 0.991 
(0.899–1.093)
0.860





















0.293 0.594 1.340 
(0.418–4.294)
0.623
TLC 0.000 0.000 1.000 
(1.000–1.000)
0.913
ABG pH −1.760 3.620 0.172 
(0.000–207.369)
0.627





−0.094 0.035 0.910 
(0.850–0.976)
0.008
SE = standard error; OR = odds ratio; CI = confidence interval; SBP = sys-
tolic blood pressure; TLC = total leukocyte count; ABG = arterial blood 
gas; HCO3 = bicarbonate; LOS = length of stay.
*Assessed via random blood glucose tests. †Defined as either hyperglycaemia 
(random blood glucose levels of >200 mg/dL) or hypoglycaemia (random 
blood glucose levels of <55 mg/dL).
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 Strengths of the current study include its sample 
size and the evaluation of both hyper- and hypogly-
caemia as predictors of mortality. However, the results 
are limited by the absence of any long-term follow-up 
of the survivors and the lack of analysis of other factors 
which may play a role in glucose homeostasis, such as 
serum calcium, magnesium, phosphate, insulin and cor- 
tisol levels.
Conclusion
As a result of several complex mechanisms, AlP poisoning 
can cause both hyper- and hypoglycaemia. However, 
the role of blood glucose levels and blood glucose alter- 
ations in predicting patient outcomes in AlP poisoning 
cases remains inconclusive. The authors recommend that 
further studies with larger sample sizes be conducted to 
evaluate other factors involved in glucose homeostasis.
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